RecruitingNCT04354545
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Sponsor
University of California, Los Angeles
Enrollment
75 participants
Start Date
Apr 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
Eligibility
Inclusion Criteria3
- Currently using one or more topical glaucoma antihypertensives
- Self-described symptoms of ocular surface discomfort
- Xiidra is being prescribed as part of the subject's standard care
Exclusion Criteria4
- History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),
- current use of topical cyclosporine
- current use of topical steroids
- incisional ocular surgery within 6 months
Interventions
DRUGXiidra (Lifitegrast ophthalmic solution) 5%
FDA approved lifitegrast opthalmic solution eye drop
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04354545
Related Trials
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
NCT066829621 location
Automated Applanation Tonometry - Updated
NCT072983561 location
Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years
NCT074607911 location
Modified Trabeculectomy After Failure of Combined Phaco With GATT
NCT074557861 location
Community Based Treatment for (ComBaT) Glaucoma
NCT061245212 locations